# Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

> **NCT04125693** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 1 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Rogaratinib (BAY1163877)
- **DRUG:** Combination drug

## Key facts

- **NCT ID:** NCT04125693
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-30
- **Primary completion:** 2021-02-16
- **Final completion:** 2021-02-16
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04125693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04125693, "Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04125693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*